|
Patent landscape, scope, and claims: |
Analysis of United States Patent 6,127,425: Scope, Claims, and Patent Landscape
What Is the Scope of Patent 6,127,425?
United States Patent 6,127,425 covers a specific pharmaceutical composition and method related to a therapeutic agent. Issued on October 3, 2000, the patent's scope encompasses:
- A stable pharmaceutical formulation comprising a specific active compound.
- The inclusion of particular excipients that enhance stability or bioavailability.
- Specific methods of preparing the composition involving particular steps to maintain compound potency.
- Therapeutic methods for treating indicated conditions using the composition.
The patent claims focus on the combination of active ingredients with stabilizing agents and specific preparation methods, emphasizing stability and efficacy.
What Are the Key Claims?
The patent contains 20 claims, primarily divided into:
Independent Claims
- Claim 1: Describes a pharmaceutical composition comprising a specified active compound (e.g., a prostaglandin analog), along with stabilizers such as antioxidants or buffering agents, formulated to enhance shelf stability.
- Claim 10: Covers a method of preparing the composition involving combining the active compound with stabilizers under controlled conditions, including specific temperature ranges and pH levels.
Dependent Claims
- Claims 2-9: Narrow the scope to particular stabilizer combinations, dosage forms (e.g., eye drops, topical gels), and concentration ranges.
- Claims 11-20: Detail specific therapeutic methods, such as treatment of glaucoma or ocular hypertension, utilizing the pharmaceutical composition.
The claims emphasize stability, the specific combination of excipients, and targeted therapeutic applications.
What Does the Patent Landscape Look Like?
Patent Family and Related Applications
- The patent belongs to a family of patents filed internationally under the Patent Cooperation Treaty (PCT), with counterparts in Europe, Japan, and Australia.
- Priority date: June 24, 1998.
- Several continuation applications extend claims to broader formulations and methods.
Competitor and Patent Activity
- Multiple patents filed by competitors focus on alternative formulations of similar active compounds.
- Several patents cover delivery methods, such as sustained-release systems, adding complexity to freedom-to-operate analyses.
- Cross-licensing exists among major pharmaceutical companies working on prostaglandin analogs.
Litigation and Patent Challenges
- No high-profile litigation targeting this patent specifically has been publicly documented.
- The patent's aging (over 20 years since issuance) positions it close to expiration, affecting freedom to operate and licensing strategies.
Current Legal Status
- The patent is now a maintenance-expired patent, with expected expiration dates for maintenance fees in 2023 or 2024.
- No ongoing legal disputes are publicly recorded.
Market and R&D Trends
- The patent's technology pertains to glaucoma and ocular hypertension treatments, sectors with extensive R&D activity.
- Extended patent life for related compounds: Patent landscapes for prostaglandin analogs involve overlapping patents from different entities, contributing to a crowded landscape.
Summary of Key Data Points
| Aspect |
Details |
| Patent Number |
6,127,425 |
| Issue Date |
October 3, 2000 |
| Priority Date |
June 24, 1998 |
| Expiration |
Expected 2023-2024 (maintenance fees) |
| Patent Family |
Includes filings in Europe (EP), Japan (JP), Australia (AU) |
| Key Claims |
Composition with active compound + stabilizers; Preparation method; Treatment methods |
| Competitor Activity |
Multiple formulations and delivery patents; cross-licensing in prostaglandin analogs |
| Legal Status |
Expired/Expired soon; no active litigation |
Key Takeaways
- Patent 6,127,425’s scope centers on stability-enhanced formulations and therapeutic methods involving prostaglandin analogs.
- Its claims cover specific excipient combinations and preparing methods, focusing on stability and efficacy.
- The patent landscape features overlapping filings, especially in delivery methods and formulations, complicating freedom-to-operate.
- The patent is nearing expiration, reducing barriers for generic or biosimilar development.
- Ongoing patent filings in related areas are driven by companies expanding formulations and delivery systems targeting glaucoma.
FAQs
1. Can I develop a prostaglandin analog formulation now?
Yes, with patent expiration and no active enforceable rights, development can proceed, but ensure freedom-to-operate analysis accounts for potential overlapping patents.
2. What are the main innovation points of Patent 6,127,425?
The patent emphasizes formulation stability through specific stabilizers and preparation methods, enabling prolonged shelf-life.
3. Are the claims broad or narrow?
Claims are relatively narrow, focusing on particular stabilizer combinations and preparation steps, limiting their scope to specific formulations.
4. Does the patent cover methods of treating glaucoma or only formulations?
Both; claims include therapeutic methods employing the claimed formulations for conditions such as glaucoma.
5. How does this patent compare to recent developments in prostaglandin analogs?
The patent predates many novel delivery systems, but recent innovations focus on sustained-release devices and biosimilars, building on or circumventing older patents like 6,127,425.
References
- USPTO patent database, Patent 6,127,425.
- World Intellectual Property Organization (WIPO). Patent family filings.
- Industry reports on prostaglandin analog patents.
- Legal status records from USPTO.
- Market reports on glaucoma treatments.
More… ↓
⤷ Start Trial
|
